These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

469 related articles for article (PubMed ID: 29209403)

  • 1. Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy.
    Kosmas CE; DeJesus E; Morcelo R; Garcia F; Montan PD; Guzman E
    Drugs Context; 2017; 6():212511. PubMed ID: 29209403
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclase-associated protein 1 is a binding partner of proprotein convertase subtilisin/kexin type-9 and is required for the degradation of low-density lipoprotein receptors by proprotein convertase subtilisin/kexin type-9.
    Jang HD; Lee SE; Yang J; Lee HC; Shin D; Lee H; Lee J; Jin S; Kim S; Lee SJ; You J; Park HW; Nam KY; Lee SH; Park SW; Kim JS; Kim SY; Kwon YW; Kwak SH; Yang HM; Kim HS
    Eur Heart J; 2020 Jan; 41(2):239-252. PubMed ID: 31419281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure and Function of Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) in Hyperlipidemia and Atherosclerosis.
    Lu X
    Curr Drug Targets; 2019; 20(10):1029-1040. PubMed ID: 30767742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives (THPBs) as proprotein convertase subtilisin/kexin type 9 (PCSK9) modulators for the treatment of hyperlipidemia.
    Wu C; Xi C; Tong J; Zhao J; Jiang H; Wang J; Wang Y; Liu H
    Acta Pharm Sin B; 2019 Nov; 9(6):1216-1230. PubMed ID: 31867167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of proprotein convertase subtilisin/kexin type 9 inhibitors on lipid metabolism and cardiovascular function.
    Amput P; McSweeney C; Palee S; Phrommintikul A; Chattipakorn SC; Chattipakorn N
    Biomed Pharmacother; 2019 Jan; 109():1171-1180. PubMed ID: 30551367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk.
    Bergeron N; Phan BA; Ding Y; Fong A; Krauss RM
    Circulation; 2015 Oct; 132(17):1648-66. PubMed ID: 26503748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke.
    Zhang L; Song K; Zhu M; Shi J; Zhang H; Xu L; Chen Y
    Int J Neurosci; 2016 Aug; 126(8):675-80. PubMed ID: 26040332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies.
    Seidah NG; Prat A; Pirillo A; Catapano AL; Norata GD
    Cardiovasc Res; 2019 Mar; 115(3):510-518. PubMed ID: 30629143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia.
    Kosmas CE; Muñoz Estrella A; Sourlas A; Silverio D; Hilario E; Montan PD; Guzman E
    Diseases; 2018 Jul; 6(3):. PubMed ID: 30011788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 and cancer: Rethinking the link.
    Mahboobnia K; Pirro M; Marini E; Grignani F; Bezsonov EE; Jamialahmadi T; Sahebkar A
    Biomed Pharmacother; 2021 Aug; 140():111758. PubMed ID: 34058443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration.
    Zaid A; Roubtsova A; Essalmani R; Marcinkiewicz J; Chamberland A; Hamelin J; Tremblay M; Jacques H; Jin W; Davignon J; Seidah NG; Prat A
    Hepatology; 2008 Aug; 48(2):646-54. PubMed ID: 18666258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure-function relation to therapeutic inhibition.
    Tibolla G; Norata GD; Artali R; Meneghetti F; Catapano AL
    Nutr Metab Cardiovasc Dis; 2011 Nov; 21(11):835-43. PubMed ID: 21943799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polydatin ameliorates low-density lipoprotein cholesterol and lipid metabolism by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9) in triple-negative breast cancer with hyperlipidemia.
    Liu M; Zhang Q
    Am J Cancer Res; 2024; 14(1):52-72. PubMed ID: 38323270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture.
    Mbikay M; Sirois F; Simoes S; Mayne J; Chrétien M
    FEBS Open Bio; 2014; 4():755-62. PubMed ID: 25349780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.